2024 Annual Review
Our 2024 Annual Review explores progress on our innovative finance agreements, key milestones reached across the year, and our latest impact data.
Learn more about how our market shaping work is accelerating access to healthcare products.
26 June 2025
At MedAccess, we broker and finance agreements to get affordable medical innovations into the hands of the people who need them most. We do not do this alone. We work alongside remarkable partners in industry, health ministries, global health organisations, service delivery, academia and civil society. Trust and collaboration are at the heart of our success.
Our 2024 Annual Review outlines progress in accelerating access to products that tackle life-threatening illnesses including HIV, tuberculosis and malaria as well as preparations to play an increasing role in tackling non-communicable diseases.
Key highlights include the nationwide rollout of G6PD testing and single use tafenoquine to tackle P. vivax malaria in Brazil, children in Cameroon receiving RTS,S – the world’s first malaria vaccine – and preparation for MedAccess’ agreements on radiotherapy treatment for cancer and vitamin A supplements for food fortification.
Despite global challenges, we made strong progress in 2024. Together, let’s make sure everyone, everywhere, can access the medicines they need, when they need them.
Our impact
We are pleased to share our key impact highlights to the end of 2024. Since we were formed in 2017, our agreements have:
- helped 559 million people access vaccines, diagnostics, medicines and other health technologies.
- supported partnerships that have benefitted people living in over 115 low- and middle-income countries.
- enabled suppliers to offer their products at lower prices, leading to $217 million in savings for purchasers.
